As of 2025-12-28, the EV/EBITDA ratio of Foghorn Therapeutics Inc. (FHTX) is -2.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FHTX's latest enterprise value is 216.04 mil USD. FHTX's TTM EBITDA according to its financial statements is -78.96 mil USD. Dividing these 2 quantities gives us the above FHTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.3x - 15.5x | 15.3x |
| Forward P/E multiples | 19.8x - 35.5x | 22.2x |
| Fair Price | (26.01) - (20.01) | (24.60) |
| Upside | -581.7% - -470.5% | -555.6% |
| Date | EV/EBITDA |
| 2025-12-24 | -2.74 |
| 2025-12-23 | -2.84 |
| 2025-12-22 | -3.01 |
| 2025-12-19 | -2.62 |
| 2025-12-18 | -2.45 |
| 2025-12-17 | -2.19 |
| 2025-12-16 | -2.08 |
| 2025-12-15 | -2.00 |
| 2025-12-12 | -2.05 |
| 2025-12-11 | -2.08 |
| 2025-12-10 | -2.06 |
| 2025-12-09 | -2.00 |
| 2025-12-08 | -2.06 |
| 2025-12-05 | -1.99 |
| 2025-12-04 | -2.15 |
| 2025-12-03 | -2.05 |
| 2025-12-02 | -1.94 |
| 2025-12-01 | -2.02 |
| 2025-11-28 | -2.27 |
| 2025-11-26 | -2.31 |
| 2025-11-25 | -2.25 |
| 2025-11-24 | -2.13 |
| 2025-11-21 | -2.18 |
| 2025-11-20 | -2.16 |
| 2025-11-19 | -2.35 |
| 2025-11-18 | -2.46 |
| 2025-11-17 | -2.31 |
| 2025-11-14 | -2.23 |
| 2025-11-13 | -1.99 |
| 2025-11-12 | -2.11 |
| 2025-11-11 | -2.05 |
| 2025-11-10 | -2.03 |
| 2025-11-07 | -1.99 |
| 2025-11-06 | -1.73 |
| 2025-11-05 | -1.73 |
| 2025-11-04 | -1.40 |
| 2025-11-03 | -1.88 |
| 2025-10-31 | -2.03 |
| 2025-10-30 | -1.96 |
| 2025-10-29 | -1.90 |
| 2025-10-28 | -2.06 |
| 2025-10-27 | -1.82 |
| 2025-10-24 | -1.78 |
| 2025-10-23 | -1.66 |
| 2025-10-22 | -1.74 |
| 2025-10-21 | -1.78 |
| 2025-10-20 | -1.76 |
| 2025-10-17 | -1.73 |
| 2025-10-16 | -1.96 |
| 2025-10-15 | -2.03 |